#1 Clinical Trials Search in Europe

Human Papillomavirus Type 45 L1 Protein

This article summarizes several clinical trials investigating the use of Human Papillomavirus Type 45 L1 Protein as part of a 9-valent HPV vaccine (Gardasil 9). The trials aim to evaluate the vaccine’s safety, immunogenicity, and effectiveness in various populations and conditions, including extended dosing schedules, immunocompromised patients, and treatment of HPV-related lesions. These studies provide valuable insights into optimizing HPV vaccination strategies and expanding its potential therapeutic applications.

Table of Contents

What is Human Papillomavirus Type 45?

Human Papillomavirus Type 45 (HPV45) is one of several high-risk HPV types that can cause cervical cancer and other HPV-related cancers[1]. HPV is a common sexually transmitted infection that can infect the genital areas, mouth, and throat. While most HPV infections clear on their own, persistent infection with high-risk types like HPV45 can lead to the development of cancer over time.

Vaccine Composition and Mechanism

The Human Papillomavirus Type 45 L1 Protein is one of nine HPV proteins included in the 9-valent HPV vaccine, also known as Gardasil 9[1]. This vaccine contains virus-like particles (VLPs) made from the L1 protein of HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58. These VLPs are produced using recombinant DNA technology in yeast cells.

When administered, the vaccine stimulates the immune system to produce antibodies against these HPV types. These antibodies can then neutralize the actual virus if a person is exposed in the future, preventing infection and the potential development of HPV-related diseases[1].

Indications and Uses

The 9-valent HPV vaccine containing the HPV45 L1 protein is indicated for the prevention of:

  • Cervical, vulvar, vaginal, and anal cancers caused by HPV types 16, 18, 31, 33, 45, 52, and 58
  • Genital warts caused by HPV types 6 and 11
  • Precancerous or dysplastic lesions caused by the 9 HPV types covered by the vaccine

It is approved for use in both males and females, typically starting from age 9 through 45 years[1][1].

Dosing and Administration

The standard dosing schedule for the 9-valent HPV vaccine is:

  • For individuals 9-14 years old: 2 doses given 6-12 months apart
  • For individuals 15 years and older: 3 doses, with the second dose given 2 months after the first, and the third dose given 6 months after the first

The vaccine is administered as an intramuscular injection, typically in the upper arm or thigh[1][1].

Efficacy and Immune Response

Clinical trials have shown that the 9-valent HPV vaccine, including the HPV45 L1 protein component, is highly effective in preventing HPV infection and related diseases. The vaccine induces a strong immune response, with high levels of antibodies produced against all nine HPV types[1].

One study is investigating the vaccine’s efficacy in preventing oral persistent HPV infection in adult males aged 20-45 years[2]. This research may expand our understanding of the vaccine’s protective effects beyond anogenital infections.

Safety and Side Effects

The 9-valent HPV vaccine has been extensively tested and is considered safe for use. Common side effects may include:

  • Pain, swelling, or redness at the injection site
  • Headache
  • Fever
  • Nausea
  • Dizziness

Serious adverse events are rare. As with any vaccine, severe allergic reactions are possible but extremely uncommon[1][1].

Use in Special Populations

Research is ongoing to evaluate the use of the 9-valent HPV vaccine in special populations. For example:

  • A study is investigating the immunogenicity of the vaccine in immunocompromised children and adolescents, including those with HIV, organ transplant recipients, and patients who have undergone chemotherapy[3].
  • Another trial is examining the efficacy of HPV vaccination after allogeneic stem cell transplantation, comparing early (9 months post-transplant) versus late (15 months post-transplant) vaccination[4].

Ongoing Research

Several clinical trials are currently exploring new applications and dosing strategies for the 9-valent HPV vaccine:

  • A study is evaluating extended 2-dose regimens with longer intervals between doses in 9-14 year olds, compared to the standard 3-dose regimen in 16-26 year old women[1].
  • Research is investigating the use of the vaccine as an adjuvant treatment for women with vulvar high-grade squamous intraepithelial lesions (vHSIL)[5].
  • A trial is assessing the effectiveness of HPV vaccination in women over 45 years old who have been treated for high-grade cervical lesions[6].
  • Another study is exploring the potential of the vaccine to treat difficult-to-treat palmar or plantar warts in patients who haven’t responded to previous treatments[7].

These ongoing studies may lead to new recommendations for HPV vaccination and expand its potential therapeutic applications beyond prevention.

Trial Aspect Details
Vaccine Composition 9-valent HPV vaccine (Gardasil 9) containing L1 proteins from HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58
Main Objectives Evaluate safety, immunogenicity, and efficacy in various populations and conditions
Target Populations Children/adolescents (9-14 years), adults (16-45 years), immunocompromised patients, women with vHSIL, patients with warts
Key Outcomes Antibody responses, seroconversion rates, HPV infection/lesion incidence, safety profile, quality of life improvements
Study Designs Randomized controlled trials, open-label studies, extended dosing interval evaluations
Follow-up Periods Range from 12 months to 10 years post-vaccination
Potential Applications Optimized vaccination schedules, therapeutic use in HPV-related conditions, post-treatment vaccination strategies

FAQ

  • What is the main purpose of these clinical trials? The main purpose of these clinical trials is to evaluate the safety, immunogenicity, and effectiveness of the 9-valent HPV vaccine (Gardasil 9), which includes Human Papillomavirus Type 45 L1 Protein, in various populations and conditions. The trials aim to optimize vaccination strategies and explore potential therapeutic applications.
  • Who are the target populations for these clinical trials? The target populations vary across the trials and include children and adolescents aged 9-14, adults aged 16-26, immunocompromised patients, women with vulvar high-grade squamous intraepithelial lesions (vHSIL), and patients with difficult-to-treat palmar or plantar warts.
  • What are some of the key outcomes being measured in these trials? Key outcomes being measured include antibody responses to HPV types, seroconversion rates, incidence of HPV-related infections and lesions, safety and tolerability of the vaccine, and quality of life improvements in patients with HPV-related conditions.
  • How long do these clinical trials typically last? The duration of these clinical trials varies, but many of them involve follow-up periods ranging from 12 months to several years. Some trials include long-term follow-up assessments at 2, 5, and 10 years post-vaccination.
  • Are there any potential benefits for participants in these clinical trials? Potential benefits for participants include access to a novel vaccination schedule or therapeutic application of the HPV vaccine, close monitoring of their health status, and the opportunity to contribute to the advancement of medical knowledge in HPV prevention and treatment.

Ongoing Clinical Trials on Human Papillomavirus Type 45 L1 Protein

  • Study on HPV Vaccine Timing for Patients After Stem Cell Transplantation Using Gardasil 9

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Sweden

Glossary

  • Human Papillomavirus (HPV): A group of viruses that can cause various types of cancer and genital warts. There are many different types of HPV, including type 45, which is targeted by the vaccine in these trials.
  • 9-valent HPV vaccine (Gardasil 9): A vaccine that protects against nine types of HPV, including type 45. It contains virus-like particles of the L1 protein from each HPV type, produced using recombinant DNA technology.
  • Immunogenicity: The ability of a substance, such as a vaccine, to provoke an immune response in the body. In these trials, it's often measured by antibody levels and seroconversion rates.
  • Seroconversion: The development of detectable antibodies in the blood against a specific antigen, such as HPV. It indicates that the immune system has responded to the vaccine.
  • Geometric Mean Titer (GMT): A measure of the average antibody level in a group of participants, calculated using the geometric mean of individual antibody titers.
  • High-grade Squamous Intraepithelial Lesion (HSIL): Abnormal, precancerous changes in the cells of the cervix, vulva, or other areas that can be caused by persistent HPV infection.
  • Allogeneic Stem Cell Transplantation: A procedure where a patient receives stem cells from a genetically similar, but not identical, donor to treat various blood and immune system disorders.
  • Competitive Luminex Immunoassay (cLIA): A laboratory technique used to measure antibody levels against specific HPV types in blood samples.
  • Recombinant vaccine: A vaccine produced using genetic engineering techniques to create proteins from the target pathogen, in this case, HPV L1 proteins.
  • Persistent infection: An infection that remains in the body for an extended period, often defined as 6 months or longer in the context of HPV infections.

References

  1. http://clinicaltrials.eu/trial-id/2022-500256-37-00
  2. http://clinicaltrials.eu/trial-id/2022-501974-21-00
  3. http://clinicaltrials.eu/trial-id/2022-501413-31-00
  4. http://clinicaltrials.eu/trial/study-on-hpv-vaccine-timing-for-patients-after-stem-cell-transplantation-using-gardasil-9/
  5. http://clinicaltrials.eu/trial/study-on-hpv-vaccine-for-women-with-vulvar-hsil-evaluating-the-effectiveness-of-nonavalent-hpv-vaccine-in-preventing-recurrence-of-vulvar-high-grade-lesions/
  6. http://clinicaltrials.eu/trial/study-on-hpv-vaccine-after-treatment-for-high-grade-cervical-lesions-in-women-over-45/
  7. http://clinicaltrials.eu/trial/study-on-the-effectiveness-of-the-nonavalent-hpv-vaccine-in-treating-hard-to-treat-palmar-or-plantar-warts-in-patients-who-have-not-responded-to-two-previous-treatments/